

11 October 2024

COVID Treatments

In the 6 months to September 2024, can you tell me how many patients have been treated with the following products specifically under NICE Guidance NG191 "COVID-19 rapid guideline: managing COVID-19"?

Antivirals

Sotrovimab

Corticosteroids

Casirivimab and imdevimab – for people hospitalised because of COVID-19

Tocilizumab

Baricitinib

Antibiotics

Azithromycin

Budesonide (inhaled)

Colchicine

Doxycycline

Ivermectin

Tixagevimab plus cilgavimab

Vitamin D

We are unable to provide this information as this data is not held centrally and in order to retrieve this information, the service would need to undertake a manual trawl of patient records. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.